Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450157 · ClinicalTrials.gov registry record
A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 6,448
- Enrollment target
NCT07450157 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 6,448 participants.
The verdict
NCT07450157 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 6,448 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific Membrane Antigen-617 (177Lu-PSMA-617). Patient data from multiple electronic health record databases, including claims (open-source medical and pharmacy claims), consumer attributes, mortality, and laboratory data linked to claims databases was used. The study analysis was conducted in two phases. Phase I provided an early view of patients treated with 177Lu-PSMA-617 shortly after launch. Phase II refreshed the data, added mortality and extracted additional years of historical data to allow for the identification of the initial metastatic castrate-resistant prostate cancer (mCRPC) diagnosis and follow-up from that date through the start of 177Lu-PSMA-617.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,448 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2025-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07450157
The ClinicalTrials.gov registry entry for NCT07450157 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07450157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07450157 about?
NCT07450157 is a clinical study titled "A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617". The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific Membrane Antigen-617 (177Lu-PSMA-617). Patient data from multiple electronic...
What is the current status of trial NCT07450157?
This trial is currently completed. The enrollment target is 6,448 participants. The study started on 2023-06-23. Estimated completion is 2025-02-28.
Who is sponsoring clinical trial NCT07450157?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.